Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Eight-Week, Multicenter, Randomized, Double-blind, Placebo-controlled Study, to Evaluate the Efficacy, Safety and Tolerability of Two Fixed Doses (100 and 30 mg Once Daily) of Saredutant in Patients With Generalized Anxiety Disorder

NCT00390533 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT00390533
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00390533 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Eight-Week, Multicenter, Randomized, Double-blind, Placebo-controlled Study, to Evaluate the Efficacy, Safety and Tolerability of Two Fixed Doses (100 and 30 mg Once Daily) of Saredutant in Patients With Generalized Anxiety Disorder
Lead sponsor
Sanofi
Phase
Phase 3
Overall status
Completed
Start date
September 30, 2006
Completion date
February 29, 2008
Enrollment
428 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

generalized anxiety